Description
Background:
Blinatumomab, marketed under the brand name BLINCYTO, is a monoclonal antibody used in the treatment of certain types of leukemia. It is specifically designed to target and bind to both CD19, a protein found on the surface of B cells, and CD3, a protein on the surface of T cells. Blinatumomab brings these immune cells into close proximity, facilitating the destruction of B cells by the activated T cells. BLINCYTO is approved for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in both pediatric and adult patients. This immunotherapy has demonstrated efficacy in patients who have not responded to other treatments or have experienced relapse, offering a novel approach to the management of this aggressive form of leukemia by harnessing the immune system’s ability to target and eliminate cancer cells